(Q40501526)

21 September 2017

title

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo (English)

1 reference

21 September 2017

Weisberg E

1

1 reference

21 September 2017

Catley L

2

1 reference

21 September 2017

Kujawa J

3

1 reference

21 September 2017

Atadja P

4

1 reference

21 September 2017

Remiszewski S

5

1 reference

21 September 2017

Fuerst P

6

1 reference

21 September 2017

Cavazza C

7

1 reference

21 September 2017

Anderson K

8

1 reference

21 September 2017

Griffin JD

9

1 reference

21 September 2017

publication date

1 December 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

18

1 reference

21 September 2017

issue

12

1 reference

21 September 2017

page(s)

1951-1963

1 reference

Histone deacetylases and cancer: causes and therapies

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Transcriptional activators direct histone acetyltransferase complexes to nucleosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Histone acetylation at promoters is differentially affected by specific activators and repressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Histone acetylation and chromatin assembly: a single escort, multiple dances?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Histone acetylation-mediated regulation of genes in leukaemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Structural organization of the bcr gene and its role in the Ph' translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Chronic oral administration of CI-994: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

7 January 2021

Cell differentiation in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

7 January 2021

Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

7 January 2021

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403519

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403519

1 reference

Dimensions Publication ID

21 September 2017

1011779634

0 references

1 reference